Vorsetuzumab mafodotin

Vorsetuzumab mafodotin
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	CD70
Clinical data
Other names	SGN-75
ATC code	none;
Legal status
Legal status	Discontinued;
Identifiers
CAS Number	1165741-01-4;
ChemSpider	none;
KEGG	D10341;
Chemical and physical data
Formula	C6476H10006N1726O2028S50(C49H78N6O11)3-5
Molar mass	150 kg/mol

Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer.^[1] It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.

This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma,^[2] but development was discontinued in 2013.^[3] No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.^[3]

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin, American Medical Association.
^ Clinical trials for SGN-75 "Clinicaltrials.gov"
^ ^a ^b Seattle Genetics Third Quarter 2013 Financial Report

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin, American Medical Association.

[2] Clinical trials for SGN-75 "Clinicaltrials.gov"

[SG3Q2013-3] Seattle Genetics Third Quarter 2013 Financial Report

[1]

[2]

[3]